Association of JAK-STAT pathway related genes with lymphoma risk: Results of a European case-control study (EpiLymph)

British Journal of Haematology

Volumn 153, Issue 3, 2011, Pages 318-333

  Butterbach, Katja ^a   Beckmann, Lars ^a   de Sanjosé, Silvia ^b,c   Benavente, Yolanda ^b,c   Becker, Nikolaus ^a   Foretova, Lenka ^d   Maynadie, Marc ^e   Cocco, Pierluigi ^f   Staines, Anthony ^g   Boffetta, Paolo ^h,i   Brennan, Paul ^j   Nieters, Alexandra ^k,l  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f UNIVERSITY OF CAGLIARI   (Italy)

^g DUBLIN CITY UNIVERSITY   (Ireland)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^j INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^k Molecular Epidemiology   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

Association study; Epidemiology; Janus kinase signal transducer and activator of transcription; Lymphoma; Susceptibility

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12P35; JANUS KINASE; PROTEIN BMF; PROTEIN TP63; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; B CELL LYMPHOMA; BMF GENE; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GAMMA INTERFERON GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HODGKIN DISEASE; HUMAN; INTERLEUKIN 12A GENE; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT1 GENE; STAT3 GENE; STAT5A GENE; STAT6 GENE; SUPPRESSOR OF CYTOKINE SIGNALING 1 GENE; TP63 GENE;

ADULT; AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HODGKIN DISEASE; HUMANS; JANUS KINASES; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 79954415963     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08632.x     Document Type: Article

References (109)

1. Adamkova, L., Souckova, K. & Kovarik, J. (2007) Transcription protein STAT1: biology and relation to cancer. Folia Biologica, 53, 1-6.
2. Alexander, W.S. (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nature Reviews. Immunology, 2, 410-416.
3. de Bakker, P.I., Yelensky, R., Pe'er, I., Gabriel, S.B., Daly, M.J. & Altshuler, D. (2005) Efficiency and power in genetic association studies. Nature Genetics, 37, 1217-1223.
4. Baran-Marszak, F., Boukhiar, M., Harel, S., Laguillier, C., Roger, C., Gressin, R., Martin, A., Fagard, R., Varin-Blank, N., Ajchenbaum-Cymbalista, F. & Ledoux, D. (2010) Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica, 95, 1865-1872.
5. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
6. Baus, D. & Pfitzner, E. (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. International Journal of Cancer, 118, 1404-1413.
7. Baus, D., Nonnenmacher, F., Jankowski, S., Doring, C., Brautigam, C., Frank, M., Hansmann, M.L. & Pfitzner, E. (2009) STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia, 23, 1885-1893.
8. Belada, D., Smolej, L., Stepankova, P., Kralickova, P. & Freiberger, T. (2010) Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy. Leukemia Research, 34, e232-e234.
9. Benekli, M., Baer, M.R., Baumann, H. & Wetzler, M. (2003) Signal transducer and activator of transcription proteins in leukemias. Blood, 101, 2940-2954.
10. Bernatsky, S., Ramsey-Goldman, R., Isenberg, D., Rahman, A., Dooley, M.A., Sibley, J., Boivin, J.F., Joseph, L., Armitage, J., Zoma, A. & Clarke, A. (2007) Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology, 46, 830-832.
11. Besson, H., Brennan, P., Becker, N., Nieters, A., De Sanjose, S., Font, R., Maynadie, M., Foretova, L., Cocco, P.L., Staines, A., Vornanen, M. & Boffetta, P. (2006) Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: a European multicenter case-control study (Epilymph). International Journal of Cancer, 119, 901-908.
12. Boffetta, P., van der Hel, O., Kricker, A., Nieters, A., de Sanjose, S., Maynadie, M., Cocco, P.L., Staines, A., Becker, N., Font, R., Mannetje, A., Goumas, C. & Brennan, P. (2008) Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma - a multicentre European case-control study. International Journal of Epidemiology, 37, 1080-1094.
13. Bollrath, J. & Greten, F.R. (2009) IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Reports, 10, 1314-1319.
14. Bowman, T., Garcia, R., Turkson, J. & Jove, R. (2000) STATs in oncogenesis. Oncogene, 19, 2474-2488.
15. Breslow, N.E. & Day, N.E. (2000) Statistical Methods in Cancer Research. IARC Scientific Publications, Lyon.
16. Bromberg, J. (2002) Stat proteins and oncogenesis. Journal of Clinical Investigation, 109, 1139-1142.
17. Bruns, H.A. & Kaplan, M.H. (2006) The role of constitutively active Stat6 in leukemia and lymphoma. Critical Reviews in Oncology/Hematology, 57, 245-253.
18. Caporaso, N.E., Goldin, L.R., Anderson, W.F. & Landgren, O. (2009) Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma. Cancer Journal, 15, 117-123.
19. Carlson, C.S., Eberle, M.A., Rieder, M.J., Yi, Q., Kruglyak, L. & Nickerson, D.A. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. American Journal of Human Genetics, 74, 106-120.
20. Chiarle, R., Simmons, W.J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J.G., Levy, D.E. & Inghirami, G. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine, 11, 623-629.
21. Cocco, P., t'Mannetje, A., Fadda, D., Melis, M., Becker, N., de Sanjose, S., Foretova, L., Mareckova, J., Staines, A., Kleefeld, S., Maynadie, M., Nieters, A., Brennan, P. & Boffetta, P. (2010) Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study. Occupational and Environmental Medicine, 67, 341-347.
22. Coppo, P., Gouilleux-Gruart, V., Huang, Y., Bouhlal, H., Bouamar, H., Bouchet, S., Perrot, C., Vieillard, V., Dartigues, P., Gaulard, P., Agbalika, F., Douay, L., Lassoued, K. & Gorin, N.C. (2009) STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia, 23, 1667-1678.
23. Cotto, M., Cabanillas, F., Tirado, M., Garcia, M.V. & Pacheco, E. (2010) Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clinical and Translational Oncology, 12, 401-409.
24. Ding, B.B., Yu, J.J., Yu, R.Y., Mendez, L.M., Shaknovich, R., Zhang, Y., Cattoretti, G. & Ye, B.H. (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood, 111, 1515-1523.
25. Egwuagu, C.E. (2009) STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine, 47, 149-156.
26. Ekstrom Smedby, K., Vajdic, C.M., Falster, M., Engels, E.A., Martinez-Maza, O., Turner, J., Hjalgrim, H., Vineis, P., Seniori Costantini, A., Bracci, P.M., Holly, E.A., Willett, E., Spinelli, J.J., La Vecchia, C., Zheng, T., Becker, N., De Sanjose, S., Chiu, B.C., Dal Maso, L., Cocco, P., Maynadie, M., Foretova, L., Staines, A., Brennan, P., Davis, S., Severson, R., Cerhan, J.R., Breen, E.C., Birmann, B., Grulich, A.E. & Cozen, W. (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood, 111, 4029-4038.
27. El-Zein, R., Monroy, C.M., Etzel, C.J., Cortes, A.C., Xing, Y., Collier, A.L. & Strom, S.S. (2009) Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer, 115, 1651-1659.
28. Fan, J.B., Oliphant, A., Shen, R., Kermani, B.G., Garcia, F., Gunderson, K.L., Hansen, M., Steemers, F., Butler, S.L., Deloukas, P., Galver, L., Hunt, S., McBride, C., Bibikova, M., Rubano, T., Chen, J., Wickham, E., Doucet, D., Chang, W., Campbell, D., Zhang, B., Kruglyak, S., Bentley, D., Haas, J., Rigault, P., Zhou, L., Stuelpnagel, J. & Chee, M.S. (2003) Highly parallel SNP genotyping. Cold Spring Harbor Symposia on Quantitative Biology, 68, 69-78.
29. Fan, J.B., Gunderson, K.L., Bibikova, M., Yeakley, J.M., Chen, J., Wickham Garcia, E., Lebruska, L.L., Laurent, M., Shen, R. & Barker, D. (2006) Illumina universal bead arrays. Methods in Enzymology, 410, 57-73.
30. Feys, T., Poppe, B., De Preter, K., Van Roy, N., Verhasselt, B., De Paepe, P., De Paepe, A. & Speleman, F. (2007) A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines. Haematologica, 92, 913-920.
31. Fisher, S.G. & Fisher, R.I. (2004) The epidemiology of non-Hodgkin's lymphoma. Oncogene, 23, 6524-6534.
32. Frank, D.A. (2003) StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treatment and Research, 115, 267-291.
33. Frenzel, A., Labi, V., Chmelewskij, W., Ploner, C., Geley, S., Fiegl, H., Tzankov, A. & Villunger, A. (2010) Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood, 115, 995-1005.
34. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., Ward, R., Lander, E.S., Daly, M.J. & Altshuler, D. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
35. Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. & Herman, J.G. (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood, 101, 2784-2788.
36. Gao, X., Starmer, J. & Martin, E.R. (2008) A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genetic Epidemiology, 32, 361-369.
37. Garcia, J.F., Camacho, F.I., Morente, M., Fraga, M., Montalban, C., Alvaro, T., Bellas, C., Castano, A., Diez, A., Flores, T., Martin, C., Martinez, M.A., Mazorra, F., Menarguez, J., Mestre, M.J., Mollejo, M., Saez, A.I., Sanchez, L. & Piris, M.A. (2003) Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 101, 681-689.
38. Gayed, M., Bernatsky, S., Ramsey-Goldman, R., Clarke, A. & Gordon, C. (2009) Lupus and cancer. Lupus, 18, 479-485.
39. Hartmann, S., Martin-Subero, J.I., Gesk, S., Husken, J., Giefing, M., Nagel, I., Riemke, J., Chott, A., Klapper, W., Parrens, M., Merlio, J.P., Kuppers, R., Brauninger, A., Siebert, R. & Hansmann, M.L. (2008) Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica, 93, 1318-1326.
40. Hazan-Halevy, I., Harris, D., Liu, Z., Liu, J., Li, P., Chen, X., Shanker, S., Ferrajoli, A., Keating, M.J. & Estrov, Z. (2010) STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood, 115, 2852-2863.
41. He, C., Kraft, P., Chasman, D.I., Buring, J.E., Chen, C., Hankinson, S.E., Pare, G., Chanock, S., Ridker, P.M. & Hunter, D.J. (2010) A large-scale candidate gene association study of age at menarche and age at natural menopause. Human Genetics, 128, 515-527.
42. Hirschhorn, J.N. & Altshuler, D. (2002) Once and again-issues surrounding replication in genetic association studies. Journal of Clinical Endocrinology and Metabolism, 87, 4438-4441.
43. Hjalgrim, H. & Engels, E.A. (2008) Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. Journal of Internal Medicine, 264, 537-548.
44. Holtick, U., Vockerodt, M., Pinkert, D., Schoof, N., Sturzenhofecker, B., Kussebi, N., Lauber, K., Wesselborg, S., Loffler, D., Horn, F., Trumper, L. & Kube, D. (2005) STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia, 19, 936-944.
45. Hu, X. & Ivashkiv, L.B. (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity, 31, 539-550.
46. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC PRess, Lyon.
47. Jardin, F., Ruminy, P., Bastard, C. & Tilly, H. (2007) The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathologie-Biologie, 55, 73-83.
48. Johnson, R.C., Nelson, G.W., Troyer, J.L., Lautenberger, J.A., Kessing, B.D., Winkler, C.A. & O'Brien, S.J. (2010) Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genomics, 11, 724.
49. Kabesch, M., Schedel, M., Carr, D., Woitsch, B., Fritzsch, C., Weiland, S.K. & von Mutius, E. (2006) IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. Journal of Allergy and Clinical Immunology, 117, 269-274.
50. Kashef, M.A., Kashef, S., Handjani, F. & Karimi, M. (2006) Hodgkin lymphoma developing in a 4.5-year-old girl with hyper-IgE syndrome. Pediatric Hematology and Oncology, 23, 59-63.
51. Kim, B.H., Yin, C.H., Guo, Q., Bach, E.A., Lee, H., Sandoval, C., Jayabose, S., Ulaczyk-Lesanko, A., Hall, D.G. & Baeg, G.H. (2008) A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Molecular Cancer Therapeutics, 7, 2672-2680.
52. Kim, K., Cho, S.K., Sestak, A., Namjou, B., Kang, C. & Bae, S.C. (2009) Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 69, 1247-1250.
53. Kube, D., Holtick, U., Vockerodt, M., Ahmadi, T., Haier, B., Behrmann, I., Heinrich, P.C., Diehl, V. & Tesch, H. (2001) STAT3 is constitutively activated in Hodgkin cell lines. Blood, 98, 762-770.
54. Kupferman, M.E., Jayakumar, A., Zhou, G., Xie, T., Dakak-Yazici, Y., Zhao, M., Ju, J., Mandal, M., Jasser, S., Madden, T., Myers, J.N. & Priebe, W. (2009) Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. Journal of Experimental Therapeutics and Oncology, 8, 117-127.
55. Labi, V., Erlacher, M., Kiessling, S., Manzl, C., Frenzel, A., O'Reilly, L., Strasser, A. & Villunger, A. (2008) Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. Journal of Experimental Medicine, 205, 641-655.
56. Lam, L.T., Wright, G., Davis, R.E., Lenz, G., Farinha, P., Dang, L., Chan, J.W., Rosenwald, A., Gascoyne, R.D. & Staudt, L.M. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood, 111, 3701-3713.
57. Lan, Q., Morton, L.M., Armstrong, B., Hartge, P., Menashe, I., Zheng, T., Purdue, M.P., Cerhan, J.R., Zhang, Y., Grulich, A., Cozen, W., Yeager, M., Holford, T.R., Vajdic, C.M., Davis, S., Leaderer, B., Kricker, A., Schenk, M., Zahm, S.H., Chatterjee, N., Chanock, S.J., Rothman, N. & Wang, S.S. (2009) Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood, 114, 264-267.
58. Landgren, O. & Caporaso, N.E. (2007) New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. Hematology/Oncology Clinics of North America, 21, 825-840.
59. Landgren, O., Engels, E.A., Pfeiffer, R.M., Gridley, G., Mellemkjaer, L., Olsen, J.H., Kerstann, K.F., Wheeler, W., Hemminki, K., Linet, M.S. & Goldin, L.R. (2006) Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. Journal of the National Cancer Institute, 98, 1321-1330.
60. Leonard, W.J. & O'Shea, J.J. (1998) Jaks and STATs: biological implications. Annual Review of Immunology, 16, 293-322.
61. Liu, X. (2007) STAT3 activation inhibits human bronchial epithelial cell apoptosis in response to cigarette smoke exposure. Biochemical and Biophysical Research Communications, 353, 121-126.
62. Mackenzie, G.G., Queisser, N., Wolfson, M.L., Fraga, C.G., Adamo, A.M. & Oteiza, P.I. (2008) Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. International Journal of Cancer, 123, 56-65.
63. Martini, M., Hohaus, S., Petrucci, G., Cenci, T., Pierconti, F., Massini, G., Teofili, L., Leone, G. & Larocca, L.M. (2008) Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. American Journal of Clinical Pathology, 129, 472-477.
64. Mellemkjaer, L., Pfeiffer, R.M., Engels, E.A., Gridley, G., Wheeler, W., Hemminki, K., Olsen, J.H., Dreyer, L., Linet, M.S., Goldin, L.R. & Landgren, O. (2008) Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis and Rheumatism, 58, 657-666.
65. Melzner, I., Bucur, A.J., Bruderlein, S., Dorsch, K., Hasel, C., Barth, T.F., Leithauser, F. & Moller, P. (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood, 105, 2535-2542.
66. Mensah, F.K., Willett, E.V., Ansell, P., Adamson, P.J. & Roman, E. (2007) Non-Hodgkin's lymphoma and family history of hematologic malignancy. American Journal of Epidemiology, 165, 126-133.
67. Miligi, L., Costantini, A.S., Benvenuti, A., Kriebel, D., Bolejack, V., Tumino, R., Ramazzotti, V., Rodella, S., Stagnaro, E., Crosignani, P., Amadori, D., Mirabelli, D., Sommani, L., Belletti, I., Troschel, L., Romeo, L., Miceli, G., Tozzi, G.A., Mendico, I. & Vineis, P. (2006) Occupational exposure to solvents and the risk of lymphomas. Epidemiology, 17, 552-561.
68. Minegishi, Y. (2009) Hyper-IgE syndrome. Current Opinion in Immunology, 21, 487-492.
69. Minegishi, Y. & Karasuyama, H. (2009) Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. International Immunology, 21, 105-112.
70. Morton, L.M., Wang, S.S., Cozen, W., Linet, M.S., Chatterjee, N., Davis, S., Severson, R.K., Colt, J.S., Vasef, M.A., Rothman, N., Blair, A., Bernstein, L., Cross, A.J., De Roos, A.J., Engels, E.A., Hein, D.W., Hill, D.A., Kelemen, L.E., Lim, U., Lynch, C.F., Schenk, M., Wacholder, S., Ward, M.H., Hoar Zahm, S., Chanock, S.J., Cerhan, J.R. & Hartge, P. (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 112, 5150-5160.
71. Morton, L.M., Purdue, M.P., Zheng, T., Wang, S.S., Armstrong, B., Zhang, Y., Menashe, I., Chatterjee, N., Davis, S., Lan, Q., Vajdic, C.M., Severson, R.K., Holford, T.R., Kricker, A., Cerhan, J.R., Leaderer, B., Grulich, A., Yeager, M., Cozen, W., Hoar Zahm, S., Chanock, S.J., Rothman, N. & Hartge, P. (2009) Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiology, Biomarkers and Prevention, 18, 1259-1270.
72. Mottok, A., Renne, C., Seifert, M., Oppermann, E., Bechstein, W., Hansmann, M.L., Kuppers, R. & Brauninger, A. (2009) Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood, 114, 4503-4506.
73. Parekh, S., Polo, J.M., Shaknovich, R., Juszczynski, P., Lev, P., Ranuncolo, S.M., Yin, Y., Klein, U., Cattoretti, G., Dalla Favera, R., Shipp, M.A. & Melnick, A. (2007) BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 110, 2067-2074.
74. Pravica, V., Perrey, C., Stevens, A., Lee, J.H. & Hutchinson, I.V. (2000) A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Human Immunology, 61, 863-866.
75. Reynolds, R.J., Kelley, J.M., Hughes, L.B., Yi, N. & Bridges, Jr, S.L. (2010) Genetic association of htSNPs across the major histocompatibility complex with rheumatoid arthritis in an African-American population. Genes and Immunity, 11, 94-97.
76. Saito, M., Novak, U., Piovan, E., Basso, K., Sumazin, P., Schneider, C., Crespo, M., Shen, Q., Bhagat, G., Califano, A., Chadburn, A., Pasqualucci, L. & Dalla-Favera, R. (2009) BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 106, 11294-11299.
77. Samavati, L., Rastogi, R., Du, W., Huttemann, M., Fite, A. & Franchi, L. (2009) STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Molecular Immunology, 46, 1867-1877.
78. de Sanjose, S., Benavente, Y., Nieters, A., Foretova, L., Maynadie, M., Cocco, P.L., Staines, A., Vornanen, M., Boffetta, P., Becker, N., Alvaro, T. & Brennan, P. (2006) Association between personal use of hair dyes and lymphoid neoplasms in Europe. American Journal of Epidemiology, 164, 47-55.
79. Schedel, M., Carr, D., Klopp, N., Woitsch, B., Illig, T., Stachel, D., Schmid, I., Fritzsch, C., Weiland, S.K., von Mutius, E. & Kabesch, M. (2004) A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels. Journal of Allergy and Clinical Immunology, 114, 1100-1105.
80. Schedel, M., Frei, R., Bieli, C., Cameron, L., Adamski, J., Lauener, R. & Kabesch, M. (2009) An IgE-associated polymorphism in STAT6 alters NF-kappaB binding, STAT6 promoter activity, and mRNA expression. Journal of Allergy and Clinical Immunology, 124, 583-589, 589 e581-586.
81. Scheeren, F.A., Diehl, S.A., Smit, L.A., Beaumont, T., Naspetti, M., Bende, R.J., Blom, B., Karube, K., Ohshima, K., van Noesel, C.J. & Spits, H. (2008) IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood, 111, 4706-4715.
82. Schindler, C., Levy, D.E. & Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. Journal of Biological Chemistry, 282, 20059-20063.
83. Skibola, C.F., Curry, J.D. & Nieters, A. (2007) Genetic susceptibility to lymphoma. Haematologica, 92, 960-969.
84. Skibola, C.F., Bracci, P.M., Halperin, E., Conde, L., Craig, D.W., Agana, L., Iyadurai, K., Becker, N., Brooks-Wilson, A., Curry, J.D., Spinelli, J.J., Holly, E.A., Riby, J., Zhang, L., Nieters, A., Smith, M.T. & Brown, K.M. (2009) Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nature Genetics, 41, 873-875.
85. Skinnider, B.F. & Mak, T.W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283-4297.
86. Skinnider, B.F., Kapp, U. & Mak, T.W. (2002) The role of interleukin 13 in classical Hodgkin lymphoma. Leukemia and Lymphoma, 43, 1203-1210.
87. Smedby, K.E., Baecklund, E. & Askling, J. (2006) Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiology, Biomarkers and Prevention, 15, 2069-2077.
88. Stewart, D.A., Bahlis, N. & Mansoor, A. (2009) pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. Leukemia and Lymphoma, 50, 1276-1282.
89. The International HapMap Consortium (2003) The International HapMap Project. Nature, 426, 789-796.
90. Thomas, R.K., Re, D., Zander, T., Wolf, J. & Diehl, V. (2002) Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology, 13(Suppl. 4), 147-152.
91. Tibiletti, M.G., Martin, V., Bernasconi, B., Del Curto, B., Pecciarini, L., Uccella, S., Pruneri, G., Ponzoni, M., Mazzucchelli, L., Martinelli, G., Ferreri, A.J., Pinotti, G., Assanelli, A., Scandurra, M., Doglioni, C., Zucca, E., Capella, C. & Bertoni, F. (2009) BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Human Pathology, 40, 645-652.
92. Tomita, M., Kawakami, H., Uchihara, J.N., Okudaira, T., Masuda, M., Matsuda, T., Tanaka, Y., Ohshiro, K. & Mori, N. (2006) Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology, 3, 22.
93. Verma, N.K., Davies, A.M., Long, A., Kelleher, D. & Volkov, Y. (2010) STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cellular and Molecular Biology Letters, 15, 342-355.
94. Villeneuve, S., Orsi, L., Monnereau, A., Berthou, C., Fenaux, P., Marit, G., Soubeyran, P., Huguet, F., Milpied, N., Leporrier, M., Hemon, D., Troussard, X. & Clavel, J. (2009) Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: a French case-control study. International Journal of Cancer, 124, 1188-1195.
95. Wallet, N., Ghez, D., Delarue, R., Suarez, F., Rubio, M.T., Fischer, A., Canioni, D., Varet, B. & Hermine, O. (2007) Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clinical Lymphoma and Myeloma, 7, 425-427.
96. Wang, S.S., Cerhan, J.R., Hartge, P., Davis, S., Cozen, W., Severson, R.K., Chatterjee, N., Yeager, M., Chanock, S.J. & Rothman, N. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Research, 66, 9771-9780.
97. Wang, S.S., Slager, S.L., Brennan, P., Holly, E.A., De Sanjose, S., Bernstein, L., Boffetta, P., Cerhan, J.R., Maynadie, M., Spinelli, J.J., Chiu, B.C., Cocco, P.L., Mensah, F., Zhang, Y., Nieters, A., Dal Maso, L., Bracci, P.M., Costantini, A.S., Vineis, P., Severson, R.K., Roman, E., Cozen, W., Weisenburger, D., Davis, S., Franceschi, S., La Vecchia, C., Foretova, L., Becker, N., Staines, A., Vornanen, M., Zheng, T. & Hartge, P. (2007) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 109, 3479-3488.
98. Weidinger, S., Klopp, N., Wagenpfeil, S., Rummler, L., Schedel, M., Kabesch, M., Schafer, T., Darsow, U., Jakob, T., Behrendt, H., Wichmann, H.E., Ring, J. & Illig, T. (2004) Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. Journal of Medical Genetics, 41, 658-663.
99. Weniger, M.A., Melzner, I., Menz, C.K., Wegener, S., Bucur, A.J., Dorsch, K., Mattfeldt, T., Barth, T.F. & Moller, P. (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene, 25, 2679-2684.
100. Wu, M.C., Kraft, P., Epstein, M.P., Taylor, D.M., Chanock, S.J., Hunter, D.J. & Lin, X. (2010) Powerful SNP-set analysis for case-control genome-wide association studies. American Journal of Human Genetics, 86, 929-942.
101. Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K., Sata, M., Kohara, M. & Yoshimura, A. (2002) Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. Journal of Experimental Medicine, 196, 641-653.
102. Yu, H. & Jove, R. (2004) The STATs of cancer - new molecular targets come of age. Nature Reviews. Cancer, 4, 97-105.
103. Yu, H., Kortylewski, M. & Pardoll, D. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews. Immunology, 7, 41-51.
104. Yu, H., Pardoll, D. & Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews. Cancer, 9, 798-809.
105. Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Odum, N., Morris, S., Skorski, T. & Wasik, M.A. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology, 168, 466-474.
106. Zhang, Y., Lan, Q., Rothman, N., Zhu, Y., Zahm, S.H., Wang, S.S., Holford, T.R., Leaderer, B., Boyle, P., Zhang, B., Zou, K., Chanock, S. & Zheng, T. (2005) A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. Journal of the National Cancer Institute, 97, 1616-1618.
107. Zhang, Y., Wang, R., Holford, T.R., Leaderer, B., Zahm, S.H., Boyle, P., Zhu, Y., Qin, Q. & Zheng, T. (2007) Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 18, 351-359.
108. Zhang, C., Li, B., Zhang, X., Hazarika, P., Aggarwal, B.B. & Duvic, M. (2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. Journal of Investigative Dermatology, 130, 2110-2119.
109. Zheng, T., Blair, A., Zhang, Y., Weisenburger, D.D. & Zahm, S.H. (2002) Occupation and risk of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Journal of Occupational and Environmental Medicine, 44, 469-474.